Tuberculosis and Respiratory Diseases

  • 제56권4호
  • /
  • Pages.381-392
  • /
  • 2004
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

NCI-H157 폐암 세포주에서 Caspase Cascade 활성을 통한 Arsenic Trioxide와 Sulindac 병합요법의 세포고사효과

Inducing Apoptosis of NCI-H157 Human Lung Carcinoma Cells via Activation of Caspase Cascade by Combination Treatment with Arsenic Trioxide and Sulindac

  • 김학렬 (원광대학교 의과대학 내과학교실 원광의과학연구소) ;
  • 양세훈 (원광대학교 의과대학 내과학교실 원광의과학연구소) ;
  • 정은택 (원광대학교 의과대학 내과학교실 원광의과학연구소)
  • Kim, Hak Ryul (Department of Internal Medicine, College of Medicine Wonkwang University) ;
  • Yang, Sei Hoon (Department of Internal Medicine, College of Medicine Wonkwang University) ;
  • Jeong, Eun Taik (Department of Internal Medicine, College of Medicine Wonkwang University)
  • 발행 : 2004.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

연구배경 : Arsenic trioxide($As_2O_3$)은 재발성 또는 불응성 급성전골수성백혈병의 치료제로 쓰이는 항암제로서 비소세포폐암을 포함한 다른 암세포주에도 효과가 있는 것으로 되어있다. NSAIDs는 항암 예방약제로 사용되고 있고, 세포고사를 통해 다른 항암제나 방사선치료의 반응성을 강화시키는 것으로 알려져 있다. 저자들은 NCI-H157 세포주에서 $As_2O_3$와 sulindac의 병합치료가 그것들의 세포고사를 배가시키는지 여부를 알아보고자 하였다. 방 법 : 세포 독성은 MTT 방법으로 측정하였고, 세포고사를 알아보기 위해 핵산 염색과 유식세포 분석을 시행하였다. 세포고사의 기전을 보기 위해 caspasefamily의 활성을 보았고, PARP와 ICAD의 분절을 western blotting으로 확인하였다. 또한 Fas와 Fas-L의 발현유무를 western blotting을 통해 관찰하였다. 결 과 : NCI-H157 폐암세포에 $As_2O_3$와 sulindac을 병합치료시 단독치료군에 비해 생존율이 의미 있게 감소하였고, 이러한 세포사는 핵산염색을 통한 염색사의 응축과 핵 분절 유도와 유식세포 분석에 의한 $sub-G_0/G_1$ DNA분획의 증가현상을 통해 세포고사에 의해 매개됨을 알 수 있었다. 세포고사의 유도에는 caspase 3, 8, 9를 통한 활성화와 이에 의한 PARP와 ICAD의 절단을 확인하였다. 또한 caspase-8 protease의 활성화에는 Fas와 Fas/L 단백질의 발현증가가 유도되었음을 알 수 있었다. 결 론 :NCI-H157 폐암세포주에 $As_2O_3$와 sulindac의 병합요법은 Fas/FasL 신호전달계의 활성화와 caspase 단백질 활성화 의해 세포고사가 유도되었다.

Arsenic trioxide($As_2O_3$) was introduced into the treatment of refractory or relapsed acute promyelocytic Ieukemia. Some investigators have reported that arsenic trioxide had induced apoptosis in a variety of solid human tumor cell lines, including non-small cell lung cancer. Non-steroidal anti-inflammatory drugs(NSAIDs) are powerful chemopreventive agents for gastrointestinal cancers and the growth of established tumors are reduced by inducing apoptosis. It's also reported that NSAIDs enhanced tumor response to chemotherapeutic drugs or radiation. In this study, we aimed to determine whether combination of arsenic trioxide with sulindac augmented its apoptotic potential in NCI-H157 human lung cancer cells. The human lung cancer cell line NCI-H157 was treated with arsenic trioxide and sulindac. Cell viability was measured by the MTT assay. Apoptosis was measured by nuclear staining and flow cytometric analysis. The catalytic activity of the caspase families were measured by the fluorogenic cleavage of biosubstrates. The western blotting were also performed to define the mechanical basis of apoptosis. Combination treatment of arsenic trioxide and sulindac decreased the viability of NCI-H157 human lung cancer cells in a dose-dependent manner. The catalytic activity of caspase-3, 8 and 9 proteases were increased after combination treatment. Consistently PARP was cleaved from 116kDa to 85kDa fragments, and the expression of ICAD was decreased by time-dependent manner. Also combination treatment increased the expression of Fas and Fas/L. Combination therapy of arsenic trioxide with sulindac augments cell death and induces apoptosis via the activation of caspase cascade in NCI-H157 human lung carcinoma cells.

키워드

참고문헌

  1. Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. Atherogenicity and carcino genecity of high-arsenicartesian well water: Multiple risk factors and related malignant neoplasm of blackfoot disease. Arterio sclerosis 1988;8:452-60
  2. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder andkidney due to ingested inorganic arsenic in drinking water. Br J Cancer 1992;66:888-92
  3. Sun HD, Ma L, Hu XC, Zhang TD. Treatment of acute promyelocytic leukemiaby Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992;12:170-1
  4. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60
  5. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62:529-38
  6. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM, et al. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 1999;4:33
  7. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1992;445:59-62
  8. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK, et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancercell line PCI-1. Biochem Biophys Res Commun 1999;265:400-4
  9. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide incuces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999;82:286-92
  10. Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of hu man gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999;35:1258- 63
  11. Thun MJ, Namboodiri NM, Health CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6
  12. Harris RE, Nambodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5
  13. Scheinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer inci dence in a prospective study. Epidemiology 1994;5:138-46
  14. Smalley WE, Dubois RN. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20
  15. Dannenberg AJ, Zakim D. Chemoprevention of colon-rectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 1999;26:499-504
  16. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adeno carcinoma cells. J Clin Invest 1995;96:491-503
  17. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanism underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci 1998;95:681-6
  18. Klampfer L, Cammenga J, Wisniewski HG, Nimer SD. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 1999;93:2386-94
  19. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11: 290-9
  20. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemopre vention and chemotherapy. Expert Opin In vest Drugs 1999;8:1623-38
  21. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhancement oftumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-4
  22. Williams GT. Apoptosis in the immune system. J Pathol 1994;173:1-4
  23. Cohen JJ. Apoptosis: the physiologic pathway of cell death. Hosp Pract 1993;28:35-43
  24. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide(As2O3) in the treatment of acute promye lcytic leukemia(APL): I. As2O3 exerts dosedependent dual effects on APL cells. Blood 1997;89:3345-53
  25. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on molecular mechanisms of arsenic trioxide in the treatment of acute promyelocytic leu kemia: arsenic trioxide induces NB4 cell apoptosis with downregualation of Bcl-2 expression and modulation of PML-RARα /PML proteins. Blood 1996;88:1052-61
  26. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trio xide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-64
  27. Jung BH, Park C, Kim HR, Park MR. Arse nic trioxide induces apoptosis of HL-60 cells via activation of intrinsic caspase protease with mitochondrial dysfunction. Cancer Res and Treat 2002;34:308-15
  28. Huang S, Huang CF, Lee T. Induction of mitosis-mediated apoptosis by sodium arse nite in Hela S3 cells. Biochem Pharmacol 2000;60:771-80
  29. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000;60:3065-71
  30. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8
  31. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of NSAIDs. Eur J Cancer 1998;34:1250-9
  32. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999;59: 6178-84
  33. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, et al. Cyclooxy genase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell ines. Clin Cancer Res 2000;6:2006-11